A Novel Colon PBPK Model: Navigating the Rational Drug Design for Small-Molecule Colon-Selective Therapies.

Area of Science:

• Pharmacokinetics
• Drug Delivery
• Translational Medicine

Background:

• Developing colon-selective therapies is crucial for treating colonic diseases, but challenges in predicting human colon drug exposure hinder clinical success.
• Existing methods lack reliability for assessing colon exposure, limiting the development of targeted small-molecule drugs.

Purpose of the Study:

• To develop a physiologically based pharmacokinetic (PBPK) modeling approach for designing small-molecule colon-selective therapies.
• To guide molecular design, formulation selection, and clinical trial design for enhanced colon drug delivery.
• To address the lack of reliable methods for predicting human colon drug exposure.

Main Methods:

• Physiologically based pharmacokinetic (PBPK) modeling was employed to simulate colon drug exposure.
• Focus on achieving colon selectivity through high hepatic extraction and modified-release formulations.
• Sensitivity analyses were conducted to identify key design principles.

Main Results:

• The PBPK model successfully identified compound and formulation design principles for achieving colon selectivity.
• Demonstrated the model's utility in guiding both first-in-human and late-stage clinical trial designs.
• Established a framework for predicting colon-to-systemic drug exposure ratios.

Conclusions:

• The developed PBPK modeling approach facilitates rational drug design for colon-selective therapies.
• This approach enhances the predictability of colon drug exposure, aiding clinical trial design.
• It supports the development of effective localized treatments for colonic diseases.